Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences has applied for quotation of 1,961,158 new fully paid ordinary shares on the ASX, with an issue date of March 20, 2026. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, will expand the company’s listed share capital and may influence its capital structure and trading liquidity for investors.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. is an Australia-listed biotechnology company focused on developing and commercializing diagnostic solutions, with its shares traded on the ASX under the ticker RHY. The company operates within the life sciences and medical diagnostics industry, targeting investors seeking exposure to healthcare innovation on the Australian market.
Average Trading Volume: 992,138
Technical Sentiment Signal: Buy
Current Market Cap: A$74.45M
Learn more about RHY stock on TipRanks’ Stock Analysis page.